Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. The aim of this study was to assess the activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of . Ibrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 , 108 , 60 , 40 , 29 , 20 , 6 , 2 , 2 , and 1 isolate each of , , and . MICs were determined by the EUCAST broth microdilution method, and isolates were classified according to recommended clinical breakpoints and epidemiological cutoffs. Additionally, 22 from different clinical specimens were evaluated. Ibrexafungerp MICs ranged from 0.016 to ≥8 mg/L. The lowest ibrexafungerp MICs were observed for (geometric MIC 0.062 mg/L, MIC range 0.016-0.5 mg/L) and the highest ibrexafungerp MICs were observed for (geometric MIC 0.517 mg/L, MIC range 0.06-≥8 mg/L). Modal MICs/MIC s (mg/L) against spp. were 0.125/0.06 for , 0.5/0.5 for , 0.25/0.25 for , 0.5/0.5 for , 1/1 for , 4/2 for , and 0.5/0.5 for . Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild-type upper limits, a non-wild-type phenotype for ibrexafungerp was only observed for 16/434 (3.7%) isolates: 11 (4.6%) , 4 (5%) , and 1 (2.5%) . Ibrexafungerp showed a potent activity against .